Explore opportunities
Search by company name (Bolden, Pax, OncoLux, Nabsys), asset id, or title. Each card links to a full dossier with cited evidence.
Loading filters…
Cortical allograft kyphoplasty without PMMA—commercial early with Series A traction.
NEMIC + Commerce voucher—growth equity, not university OTL formation.
Open dossierBRF biglycan MSK regeneration—classic Brown OTL out-license with no RI startup mapped.
Preclinical academic package—physician KOL SAB + Slater seed after PoC.
Motile injectable cell therapy to accelerate meniscus and connective-tissue repair.
NIAMS R01AR080726 + R21AR077326 (Jayasuriya); large-animal next gate.
Biomimetic ECM reconstitution for musculoskeletal joint repair.
Field-of-use diligence vs XM Therapeutics before Slater-scale spinout.
RIH therapeutic approach to lower lipoprotein(a)—cardiovascular metabolic niche.
Differentiate vs Phase 3 siRNA/antisense leaders; Song lab R01HL159204 anchors cardio lipid biology.